Grifols Marks 50 Years of Transformative Plasma Medicine Production in Clayton, N.C

Grifols, a global healthcare leader renowned for its plasma-derived medicines, commemorated the 50th anniversary of its Clayton, N.C. flagship facility today. Since its inception, this site has been pivotal in delivering life-saving therapies to countless patients worldwide.

Originally established as Cutter Laboratories half a century ago, the site initially focused on producing albumin for domestic distribution. Today, the Grifols Clayton campus boasts an annual production exceeding 14 million vials of various plasma medicines, constituting 40% of the company’s global output. Its expansive portfolio now encompasses immunoglobulins, alpha-1 antitrypsin, specialty proteins, and blood clotting factors, catering to patients globally.

Expanded over the years to cover 700 acres, the Clayton facility stands as one of the largest plasma fractionation sites globally. With an annual plasma processing capacity of 12 million liters, it represents more than half of Grifols’ global capability.

Grifols’ acquisition of the site in 2011 from Talecris Biotherapeutics elevated it to a prominent position within the plasma sector. Subsequent investments exceeding USD 1 billion have significantly augmented its manufacturing capabilities, quadrupling production capacity over 13 years. This growth parallels Grifols’ global expansion, with revenues climbing from EUR 1.8 billion to EUR 6.6 billion and the employee headcount surging to over 23,000.

Thomas Glanzmann, Grifols’ Executive Chairman, attributes the Clayton site’s success to the dedication of its workforce in improving patients’ lives. Nacho Abia, Grifols’ CEO, underscores the site’s significance as a symbol of the company’s commitment to innovation and patient impact.

The Clayton facility stands as a beacon of innovation, boasting cutting-edge robotics and technology deployed throughout the manufacturing process. Its contributions extend beyond routine production, as evidenced during public health crises like the COVID-19 pandemic and Ebola outbreak, where specialized medicines were swiftly developed.

Environmental stewardship is paramount at Clayton, evident in its 300-acre wildlife habitat area and LEED-certified buildings. The site’s commitment to sustainability is further demonstrated by its Zero-Waste-to-Landfill validation and community initiatives aimed at education and workforce development.

Throughout its evolution under various names, from Cutter Laboratories to Bayer and eventually Grifols, the Clayton site has remained steadfast in its mission to produce quality medicines. Today, with over 1,600 onsite employees and an additional 400 in Research Triangle Park, Grifols continues its legacy of improving global health outcomes.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter